{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:59:26Z","timestamp":1790870366737,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aimed to characterize the clinical and neuroimaging features of hereditary leptomeningeal transthyretin amyloidosis (hATTR-LA), a dominant inheritance disorder caused by a heterozygous <jats:italic>TTR<\/jats:italic> gene mutation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A comprehensive retrospective evaluation was conducted, incorporating detailed clinical records, multimodal neuroimaging findings, and a systematic review of the literature to contextualize the observations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The patient was a 55-year-old male who presented with chronic central nervous system symptoms, including sensory-motor peripheral neuropathy and progressive visual impairment. Cerebrospinal fluid analysis revealed elevated protein levels. Neuroimaging showed progressive leptomeningeal hyperdensity on CT and characteristic linear thickening with enhancement of the leptomeninges on MRI, involving both cerebral and spinal regions. Genetic testing confirmed the diagnosis by identifying a heterozygous c.265T\u2009&gt;\u2009C (p.Y89H) pathogenic variant in exon 3 of the <jats:italic>TTR<\/jats:italic> gene, classified as pathogenic according to ACMG guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Multimodal imaging provides valuable, non-invasive insights for diagnosing hATTR-LA, enhancing diagnostic accuracy and informing clinical management of this rare condition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03736-x","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T08:36:15Z","timestamp":1746434175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hereditary leptomeningeal transthyretin amyloidosis with heterozygous TTR mutation: a case report and literature review"],"prefix":"10.1186","volume":"20","author":[{"given":"Hong-Tao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Jun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"1","key":"3736_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00415-018-9125-z","volume":"266","author":"K Fan","year":"2019","unstructured":"Fan K, Zhu H, Xu H, Mao P, Yuan L, Deng H. The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis. J Neurol. 2019;266(1):232\u201341. https:\/\/doi.org\/10.1007\/s00415-018-9125-z","journal-title":"J Neurol"},{"issue":"6","key":"3736_CR2","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","volume":"93","author":"A Carroll","year":"2022","unstructured":"Carroll A, Dyck PJ, de Carvalho M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry. 2022;93(6):668\u201378. https:\/\/doi.org\/10.1136\/jnnp-2021-327909","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"3736_CR3","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1212\/wnl.47.6.1562","volume":"47","author":"F Garzuly","year":"1996","unstructured":"Garzuly F, Vidal R, Wisniewski T, Brittig F, Budka H. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly) [published correction appears in neurology 1997;48(4):1143]. Neurology. 1996;47(6):1562\u20137. https:\/\/doi.org\/10.1212\/wnl.47.6.1562","journal-title":"Neurology"},{"issue":"9","key":"3736_CR4","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1073\/pnas.75.9.4499","volume":"75","author":"PP Costa","year":"1978","unstructured":"Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A. 1978;75(9):4499\u2013503. https:\/\/doi.org\/10.1073\/pnas.75.9.4499","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 7","key":"3736_CR5","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/brain\/123.7.1495","volume":"123","author":"D Adams","year":"2000","unstructured":"Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000;123(Pt 7):1495\u2013504. https:\/\/doi.org\/10.1093\/brain\/123.7.1495","journal-title":"Brain"},{"issue":"1","key":"3736_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s13023-022-02481-9","volume":"17","author":"X He","year":"2022","unstructured":"He X, Tian Z, Guan H, Zhang S. Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China. Orphanet J Rare Dis. 2022;17(1):337. https:\/\/doi.org\/10.1186\/s13023-022-02481-9. Published 2022 Sep 2.","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"3736_CR7","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/CM9.0000000000001094","volume":"133","author":"L Liu","year":"2020","unstructured":"Liu L, Li XB, Hu ZM, Huang SX, Tang BS, Zhang RX. Clinical and genetic features of transthyretin-related familial amyloid polyneuropathy in China. Chin Med J (Engl). 2020;133(21):2616\u20138. https:\/\/doi.org\/10.1097\/CM9.0000000000001094","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"3736_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/00019052-200010000-00011","volume":"13","author":"V Plant\u00e9-Bordeneuve","year":"2000","unstructured":"Plant\u00e9-Bordeneuve V, Said G. Transthyretin related familial amyloid polyneuropathy. Curr Opin Neurol. 2000;13(5):569\u201373. https:\/\/doi.org\/10.1097\/00019052-200010000-00011","journal-title":"Curr Opin Neurol"},{"key":"3736_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40478-015-0216-0","volume":"3","author":"JL Ziskin","year":"2015","unstructured":"Ziskin JL, Greicius MD, Zhu W, Okumu AN, Adams CM, Plowey ED. Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia. Acta Neuropathol Commun. 2015;3:43. https:\/\/doi.org\/10.1186\/s40478-015-0216-0. Published 2015 Jul 10.","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"3736_CR10","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0046-8177(89)90102-0","volume":"20","author":"T Ishihara","year":"1989","unstructured":"Ishihara T, Nagasawa T, Yokota T, Gondo T, Takahashi M, Uchino F. Amyloid protein of vessels in leptomeninges, cortices, choroid plexuses, and pituitary glands from patients with systemic amyloidosis. Hum Pathol. 1989;20(9):891\u20135. https:\/\/doi.org\/10.1016\/0046-8177(89)90102-0","journal-title":"Hum Pathol"},{"key":"3736_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","volume":"43","author":"T Damy","year":"2019","unstructured":"Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS). Eur Heart J. 2019;43:391\u2013400. https:\/\/doi.org\/10.1093\/eurheartj\/ehz173","journal-title":"Eur Heart J"},{"issue":"Pt 2","key":"3736_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/brain\/122.2.183","volume":"122","author":"M Brett","year":"1999","unstructured":"Brett M, Persey MR, Reilly MM, et al. Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain. 1999;122(Pt 2):183\u201390. https:\/\/doi.org\/10.1093\/brain\/122.2.183","journal-title":"Brain"},{"issue":"3","key":"3736_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/13506120308998998","volume":"10","author":"LH Connors","year":"2003","unstructured":"Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10(3):160\u201384. https:\/\/doi.org\/10.3109\/13506120308998998","journal-title":"Amyloid"},{"issue":"22","key":"3736_CR14","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1021\/bi027319b","volume":"42","author":"P Hammarstr\u00f6m","year":"2003","unstructured":"Hammarstr\u00f6m P, Sekijima Y, White JT, et al. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry. 2003;42(22):6656\u201363. https:\/\/doi.org\/10.1021\/bi027319b","journal-title":"Biochemistry"},{"issue":"10","key":"3736_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1212\/01.wnl.0000065901.18353.ab","volume":"60","author":"G Blevins","year":"2003","unstructured":"Blevins G, Macaulay R, Harder S, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology. 2003;60(10):1625\u201330. https:\/\/doi.org\/10.1212\/01.wnl.0000065901.18353.ab","journal-title":"Neurology"},{"issue":"3","key":"3736_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/01.lab.0000059937.11023.1f","volume":"83","author":"Y Sekijima","year":"2003","unstructured":"Sekijima Y, Hammarstr\u00f6m P, Matsumura M, et al. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest. 2003;83(3):409\u201317. https:\/\/doi.org\/10.1097\/01.lab.0000059937.11023.1f","journal-title":"Lab Invest"},{"issue":"4","key":"3736_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13506129.2019.1632829","volume":"26","author":"Y Yamada","year":"2019","unstructured":"Yamada Y, Fukushima T, Kodama S, et al. A case of cerebral amyloid angiopathy-type hereditary ATTR amyloidosis with Y69H (p.Y89H) variant displaying transient focal neurological episodes as the main symptom. Amyloid. 2019;26(4):251\u20132. https:\/\/doi.org\/10.1080\/13506129.2019.1632829","journal-title":"Amyloid"},{"issue":"10","key":"3736_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.5692\/clinicalneurol.cn-001852","volume":"63","author":"N Saito","year":"2023","unstructured":"Saito N, Kuroha Y, Hasegawa A, et al. Case of hereditary Y69H (p.Y89H) transthyretin variant leptomeningeal amyloidosis presenting with drop attacks and recurrent transient Language disorder. Rinsho Shinkeigaku. 2023;63(10):650\u20135. https:\/\/doi.org\/10.5692\/clinicalneurol.cn-001852","journal-title":"Rinsho Shinkeigaku"},{"issue":"3","key":"3736_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3129\/i09-023","volume":"44","author":"K Schweitzer","year":"2009","unstructured":"Schweitzer K, Ehmann D, Garcia R, Alport E. Oculoleptomeningeal amyloidosis in 3 individuals with the transthyretin variant Tyr69His. Can J Ophthalmol. 2009;44(3):317\u20139. https:\/\/doi.org\/10.3129\/i09-023","journal-title":"Can J Ophthalmol"},{"issue":"10","key":"3736_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/jnen\/nlaa075","volume":"79","author":"GS Quintanilha","year":"2020","unstructured":"Quintanilha GS, Cruz MW, Silva MTT, Chimelli L. Oculoleptomeningeal amyloidosis due to transthyretin p.Y89H (Y69H) variant. J Neuropathol Exp Neurol. 2020;79(10):1134\u20136. https:\/\/doi.org\/10.1093\/jnen\/nlaa075","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"3736_CR21","doi-asserted-by":"publisher","first-page":"e757","DOI":"10.1212\/CPJ.0000000000001054","volume":"11","author":"L Cechin","year":"2021","unstructured":"Cechin L, Gasmelseed J, Bashford J, et al. Early-onset leptomeningeal manifestation of G47R hereditary transthyretin amyloidosis. Neurol Clin Pract. 2021;11(5):e757\u20139. https:\/\/doi.org\/10.1212\/CPJ.0000000000001054","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"3736_CR22","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.radcr.2018.07.030","volume":"13","author":"S Beckius","year":"2018","unstructured":"Beckius S, Shah K. Intracranial and systemic manifestations of familial leptomeningeal amyloidosis, as seen on CT and MRI. Radiol Case Rep. 2018;13(6):1179\u201384. https:\/\/doi.org\/10.1016\/j.radcr.2018.07.030. Published 2018 Sep 13.","journal-title":"Radiol Case Rep"},{"issue":"8","key":"3736_CR23","first-page":"2043","volume":"26","author":"T Hirai","year":"2005","unstructured":"Hirai T, Ando Y, Yamura M, et al. Transthyretin-related familial amyloid polyneuropathy: evaluation of CSF enhancement on serial T1-weighted and fluid-attenuated inversion recovery images following intravenous contrast administration. AJNR Am J Neuroradiol. 2005;26(8):2043\u20138.","journal-title":"AJNR Am J Neuroradiol"},{"key":"3736_CR24","doi-asserted-by":"publisher","unstructured":"Auer-Grumbach M, Rettl R, Ablasser K et al. Hereditary ATTR amyloidosis in Austria: prevalence and epidemiological hot spots. J Clin Med. 2020;9(7):2234. Published 2020 Jul 14. https:\/\/doi.org\/10.3390\/jcm9072234","DOI":"10.3390\/jcm9072234"},{"issue":"7","key":"3736_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1212\/01.wnl.0000178983.20975.af","volume":"65","author":"M Nakamura","year":"2005","unstructured":"Nakamura M, Yamashita T, Ueda M, et al. Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis. Neurology. 2005;65(7):1051\u20136. https:\/\/doi.org\/10.1212\/01.wnl.0000178983.20975.af","journal-title":"Neurology"},{"key":"3736_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jocn.2015.12.017","volume":"29","author":"MB Bevers","year":"2016","unstructured":"Bevers MB, McGuone D, Jerath NU, Musolino PL. Leptomeningeal transthyretin-type amyloidosis presenting as acute hydrocephalus and subarachnoid hemorrhage. J Clin Neurosci. 2016;29:203\u20135. https:\/\/doi.org\/10.1016\/j.jocn.2015.12.017","journal-title":"J Clin Neurosci"},{"issue":"1","key":"3736_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1212\/wnl.57.1.135","volume":"57","author":"E Ellie","year":"2001","unstructured":"Ellie E, Camou F, Vital A, et al. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu). Neurology. 2001;57(1):135\u20137. https:\/\/doi.org\/10.1212\/wnl.57.1.135","journal-title":"Neurology"},{"issue":"1","key":"3736_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/cjn.2021.34","volume":"49","author":"M Alcantara","year":"2022","unstructured":"Alcantara M, Mezei MM, Baker SK, et al. Canadian guidelines for hereditary transthyretin amyloidosis polyneuropathy management. Can J Neurol Sci. 2022;49(1):7\u201318. https:\/\/doi.org\/10.1017\/cjn.2021.34","journal-title":"Can J Neurol Sci"},{"key":"3736_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2147\/TCRM.S361706","volume":"19","author":"S Dixon","year":"2023","unstructured":"Dixon S, Kang X, Quan D. Practical guidance for the use of patisiran in the management of polyneuropathy in hereditary transthyretin-mediated amyloidosis. Ther Clin Risk Manag. 2023;19:973\u201381. https:\/\/doi.org\/10.2147\/TCRM.S361706. Published 2023 Nov 27.","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"3736_CR30","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/phar.2639","volume":"41","author":"AL Warner","year":"2021","unstructured":"Warner AL. Advances in the treatment of transthyretin cardiac amyloidosis: current and emerging therapies. Pharmacotherapy. 2021;41(12):1081\u201391. https:\/\/doi.org\/10.1002\/phar.2639","journal-title":"Pharmacotherapy"},{"issue":"6","key":"3736_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03736-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03736-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03736-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T08:36:16Z","timestamp":1746434176000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03736-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3736"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03736-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee of First People\u2019s Hospital of Tianmen (ethical batch number: 20240318), and written informed consent was obtained from the participant. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}